TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total consumption of vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of Sleep Restriction Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of Sleep Restriction Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of Sleep Restriction Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence rates of traditional colorectal adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of chemotherapy induced peripheral neuropathy (CIPN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Digital MBC training rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quantitative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LURN SI-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Life satisfaction scale mean
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Respiratory volumes (tidal volume and minute volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of participants with solicited local and systemic post-injection reactions (PIRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with Adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with serious adverse events (SAEs), medically-attended adverse events (MAEs), and immune-mediated adverse events of special interest (imAESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Relative changes in perceived arthralgia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Snaith-Hamilton-Pleasure Scale (SHAPES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hamilton Depression Rating scale (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MCCB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Positive and Negative Symptoms Scale (PANSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scale for Assessment of Positive Symptoms (SAPS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scale for Assessment of Negative Symptoms (SANS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRT Classification Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Knowledge Test (SKT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Susceptibility for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of virus-specific IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in muscle strengthening activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric analysis of mid-facial recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, type, and severity of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence, nature, and severity of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite complete remission rate by Investigator per ELN 2017 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: heart failure rehospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Linaprazan PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage achieving change in low-density lipoprotein cholesterol (LDL-C) to <70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion rate of treatment cycles
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the incidence, nature and severity of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in MMSE-NR3 (Mini Mental Status Examination, Norwegian revised version)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in CDR-SB (Clinical Dementia Rating-Sum of Boxes)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: blood biomarkers (sphingolipid profile)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood biomarkers (pro-inflammatory cytokines)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: blood biomarkers (neurofilament light chain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: blood biomarkers (alpha-synuclein species)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: blood biomarkers (lipid profile)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of neuromodulation device
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of neuromodulation device use
Endpoint domain: Resource use
Primary endpoint: Number of participants evaluated for adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of participants who experience any adverse event of interest (AE-I)
Endpoint domain: Adverse events/effects
Primary endpoint: within-participant change from baseline to week 24 in the composite sum of standardized scores from the ADNI Battery Composite (ABC, 9-item)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: within-participant change from baseline to week 72 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Penn Conditional Exclusion Test (PCET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Warwick-Edinburgh Mental wellbeing Scale (WEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Brief Experiential Avoidance Questionnaire (BEAQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in transcranial magnetic stimulation evoked potential (TEP) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital/resource utilization related to adverse events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mobility (daily steps)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average transport time of the isotope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of the pelvic venous congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep stage changes as determined by Polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Insomnia Severity Index (ISI) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in scores on the Pre-Sleep Arousal Scale (PSAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of etiologic causes of necrotizing pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Shoulder flexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder disability level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Trunk impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in Peak Pruritus Numerical Rating Scale (PP-NRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Clinically Significant Lab Changes
Endpoint domain: Adverse events/effects
Primary endpoint: P-hs-CRP (mg/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LBP (μg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inclinometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy breast feeding scale (BSES-S F questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects with clinical laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with changes in the 12-lead electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment helpfulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AF/AFL occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Technical Anesthesia Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Infant Sleep Routine Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Stool inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EuroQOL-5 Dimension Questionnaire (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in therapeutic adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in tricuspid annular plane systolic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in right ventricular fractional area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bowel function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: changes in facial plate thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in facial plate height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale during lumbar flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual distress questionnaire (MEDI-Q)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality Of Life Enjoyment And Satisfaction Questionnaire Short Form(Q-LESQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of medically-attended adverse events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse events of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of performance and/or satisfaction in everyday activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived acceptability of treatment score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Respiratory rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Saturation level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term general health effects
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in brain dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the curve (AUC) in glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory reactance (Xrs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to navigate to the cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: time to bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual gastric volume that precludes adequate endoscopic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual gastric volume that necessitates premature termination of the endoscopy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for endotracheal intubation due to stomach contents
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hospital admission
Endpoint domain: Adverse events/effects
Primary endpoint: rpSO2 before and after surfactant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal flora test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in hemoglobin A1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timed Chair Stand (TCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in subjective craving levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in psychophysiological craving levels (heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in psychophysiological craving levels (heart rate variability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in psychophysiological craving levels (electrodermal activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of a blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of a blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlation between biological signature and disease stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI treatment adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implantation rate per transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Implantation rate per IVF cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancy rate per IVF cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of study completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of participants able to undergo bronchoscopic evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation as measured by SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustainable return-to-work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Early Readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Six Minute Step Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoints of ischemic stroke, systemic embolism, myocardial infarction, major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of adverse events graded by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of pathologic complete response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Assessment completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Interventionist Fidelity ratings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Metformin Peak Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Metformin blood concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rosuvastatin Peak Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Rosuvastatin blood concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digoxin Peak Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-corrected difference of Corrected QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of the missed period pills regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Complete remission with partial hematologic recovery (CRh)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anxiety level - total
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Acute Kidney Injury (AKI) Stage 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Acute Kidney Injury (AKI) Stage 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Acute Kidney Injury (AKI) Stage 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall immune reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of infection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants achieving full biochemical control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pregnancy associated plasma protein A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Clinician Administered PTSD Scale for DSM-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Checklist for DSM-5 Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulnar nerve at wrist cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radial nerve cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in NFR amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain intensity rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in heart period acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: apnea time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Horizontal deviation at apex of the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal deviation at implant shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian Phase Timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Open-conversion rate
Endpoint domain: Adverse events/effects
Primary endpoint: Endometriosis Health Profile Questionnaire (EHP 30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daily Physical Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility and acceptability of daily tDCS use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Whole-Body Protein Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RDTs IgG results: positive or negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RDTs IgG4 results: positive or negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in gut microbiome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change in gait performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in brain neuronal activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of Sharp Sensation Over Application Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Application Site Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of serious device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of Capecitabine-induced Hand-Foot Syndrome (HFS)
Endpoint domain: Adverse events/effects
Primary endpoint: Stepping reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events attributed to vaccines
Endpoint domain: Adverse events/effects